From Bioinformatics to Clinical Validation: Advance the Neoantigen Story & Achieve Potent Tumorigenic Immune Responses from Vaccine & Immunotherapies
Click here to register!
Attend our presentations
Commercializing Neoantigens: Uniting Neoantigen & Cancer Vaccines to Compete with Other Treatments for Patients
Time: 9:00AM-12:00PM EST
Day: (Workshop A) October 24, 2022
Speakers:
- Jeffrey Bockman, EVP, BioConsulting, Head of Oncology, Lumanity
- Nicole Ruggiero, CEO, EpiVax Therapeutics
Details:
Take part in the broader discussion on neoantigens in the context of a
broader consideration of where cancer vaccines are headed. Join the
leading discussion on how vaccines can outperform other treatment options
and immuno-oncology modalities. Get ahead of the curve and see how
far the field has progressed in terms of translating great ideas into clinical
reality.
- Outperforming other therapies and treatment options by translating great ideas into clinical realities
- Testing potency is not available for individualized products – how can this be solved for more off the shelf products?
- Reflecting nuances in shared vs. individualized vs. cell therapy neoantigens
Engineering Matters to Counter the Tumor Microenvironment (TME) for Better Persistence
Time: 11:30AM EST
Day: October 25, 2022
Speakers:
- Joel Sandler, PhD, Principal, BioConsulting, Cancer Cell Therapy Lead, Lumanity
- Ramon Tiu, Head Of Oncology Cell Therapy Development, Takeda
Details:
- Modifications to achieve blockade of checkpoints (e.g., PD1 KO) or other ligand signalling (e.g., TGFbeta dominant negative)
- ‘Armouring’ cells with membrane-bound or secreted cytokines
- Modulation of TME itself to increase tumor ‘warmth’
- Dual- and multi-targeting to prevent antigen escape
- Increasing the safety of therapies by adding ‘switches’ to turn on/off expression of required matters